---
schema_version: "secwatch.filing_event.v1"
accession: "0001490978-24-000071"
form_type: "8-K"
ticker: "SDGR"
cik: "0001490978"
company_name: "Schrodinger, Inc."
filed_at: "2024-07-31T23:59:59+00:00"
generated_at: "2026-05-31T14:20:35.205757+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Schrödinger Q2 rev $47.3M (+35% YoY); net loss $54.0M; updates FY guidance

## Summary
- Total revenue $47.3M (+35% YoY), software rev $35.4M (+21%), drug discovery $11.9M (+104%). Net loss $54.0M vs income $4.3M YoY.
- FY2024 guidance: software rev growth 6-13%, drug discovery $30-35M, op expense growth 8-10%, cash use above FY2023.
- Co-founded Morphic to be acquired by Lilly for ~$3.2B; Schrödinger holds 834,968 shares and low single-digit royalties.
- Launched predictive toxicology platform with $10M Gates Foundation grant and NVIDIA AI integration.
- Pipeline: SGR-1505 Phase 1 data 1H25; SGR-2921 Fast Track, data 2H25; SGR-3515 Phase 1 started, data 2H25.

## SEC filing metadata
- accession: 0001490978-24-000071
- form_type: 8-K
- ticker: SDGR
- cik: 0001490978
- company_name: Schrodinger, Inc.
- filed_at: 2024-07-31T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1490978/000149097824000071/0001490978-24-000071-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1490978/000149097824000071/sdgr-20240731.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001490978-24-000071
- JSON: https://secwatch.observer/filing/0001490978-24-000071.json
- Plain text: https://secwatch.observer/filing/0001490978-24-000071.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.